Quick Search:

uzh logo
Browse by:

Zurich Open Repository and Archive

Maintenance: Tuesday, July the 26th 2016, 07:00-10:00

ZORA's new graphical user interface will be relaunched (For further infos watch out slideshow ZORA: Neues Look & Feel). There will be short interrupts on ZORA Service between 07:00am and 10:00 am. Please be patient.

Franzen, O; van der Heyden, J; Baldus, S; Schlüter, M; Schillinger, W; Butter, C; Hoffmann, R; Corti, R; Pedrazzini, G; Swaans, M J; Neuss, M; Rudolph, V; Sürder, D; Grünenfelder, J; Eulenburg, C; Reichenspurner, H; Meinertz, T; Auricchio, A (2011). MitraClip® therapy in patients with end-stage systolic heart failure. European Journal of Heart Failure, 13(5):569-576.

Full text not available from this repository.

View at publisher



To assess the feasibility, short-term durability and clinical outcomes of MitraClip® therapy for mitral regurgitation (MR) in patients with end-stage heart failure and a severely reduced left ventricular (LV) ejection fraction.

We analysed retrospectively collected data from seven European centres. Included in the study were 50 heart failure patients [mean age 70 ± 11 years, 38 men (76%)] with a LV ejection fraction ≤25% and MR of at least grade 3+. All patients had functional MR, were in New York Heart Association (NYHA) functional class III or IV, and their mean logistic EuroSCORE was 34%. The patients underwent a total of 53 MitraClip® procedures; one or more clips were implanted in 50 procedures (48 patients), for an acute procedural success rate of 94%. Severity of MR was reduced in all successfully treated patients, 44 (92%) were discharged with MR ≤2+. Thirty-day mortality was 6%; cumulative survival at 6 months was 81.2%. Clinical and echocardiographic 6-month follow-up data were obtained from 32 and 31 successfully treated patients, respectively. At 6 months, MR ≤2+ was present in 27 (87%) of 31 patients, and 23 (72%) of 32 patients were in NYHA functional class I or II. Six-minute walk distance improved significantly, and significant reductions in LV volumes indicative of reverse LV remodelling were concordant with significant reductions in N-terminal pro-brain natriuretic peptide plasma levels.

MitraClip® therapy reduces functional MR in patients with end-stage heart failure and marked LV dysfunction and entails clinical benefit at 6 months.


123 citations in Web of Science®
156 citations in Scopus®
Google Scholar™


Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Cardiovascular Surgery
Dewey Decimal Classification:610 Medicine & health
Deposited On:26 Jan 2012 20:28
Last Modified:05 Apr 2016 15:30
Additional Information:Comment in: Eur J Heart Fail. 2011 May;13(5):472-474
Publisher DOI:10.1093/eurjhf/hfr029
PubMed ID:21471146

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page